49 related articles for article (PubMed ID: 19747027)
1. Patient adherence: a blind spot in cost-effectiveness analyses?
Rosen AB; Spaulding AB; Greenberg D; Palmer JA; Neumann PJ
Am J Manag Care; 2009 Sep; 15(9):626-32. PubMed ID: 19747027
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analyses in gynecologic oncology: methodological quality and trends.
Manuel MR; Chen LM; Caughey AB; Subak LL
Gynecol Oncol; 2004 Apr; 93(1):1-8. PubMed ID: 15047206
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analyses in obstetrics & gynecology. Evaluation of methodologic quality and trends.
Subak LL; Caughey AB; Washington AE
J Reprod Med; 2002 Aug; 47(8):631-9. PubMed ID: 12216429
[TBL] [Abstract][Full Text] [Related]
4. Costing and perspective in published cost-effectiveness analysis.
Neumann PJ
Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
[TBL] [Abstract][Full Text] [Related]
5. Adherence to multiple, prescribed medications in diabetic kidney disease: A qualitative study of consumers' and health professionals' perspectives.
Williams AF; Manias E; Walker R
Int J Nurs Stud; 2008 Dec; 45(12):1742-56. PubMed ID: 18701103
[TBL] [Abstract][Full Text] [Related]
6. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence.
Elliott RA; Barber N; Horne R
Ann Pharmacother; 2005 Mar; 39(3):508-15. PubMed ID: 15657115
[TBL] [Abstract][Full Text] [Related]
8. Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
Borah B; Sacco P; Zarotsky V
Curr Med Res Opin; 2010 Aug; 26(8):1957-65. PubMed ID: 20569067
[TBL] [Abstract][Full Text] [Related]
9. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
10. Industry sponsorship bias in cost effectiveness analysis: registry based analysis.
Xie F; Zhou T
BMJ; 2022 Jun; 377():e069573. PubMed ID: 35732297
[TBL] [Abstract][Full Text] [Related]
11. Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions.
Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):43-6. PubMed ID: 24910291
[TBL] [Abstract][Full Text] [Related]
12. Sponsorship bias in oncology cost effectiveness analysis.
Zhou T; Xie F
J Clin Epidemiol; 2023 Apr; 156():22-29. PubMed ID: 36773749
[TBL] [Abstract][Full Text] [Related]
13. Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications.
Neumann PJ; Podolsky MI; Basu A; Ollendorf DA; Cohen JT
Value Health; 2022 Jan; 25(1):59-68. PubMed ID: 35031100
[TBL] [Abstract][Full Text] [Related]
14. Quality of abstracts of papers reporting original cost-effectiveness analyses.
Rosen AB; Greenberg D; Stone PW; Olchanski NV; Neumann PJ
Med Decis Making; 2005; 25(4):424-8. PubMed ID: 16061894
[TBL] [Abstract][Full Text] [Related]
15. Can value-based design in pharmacy save money and cut heart attacks?
Kirkner RM
Manag Care; 2011 Feb; 20(2):25-8. PubMed ID: 21428126
[No Abstract] [Full Text] [Related]
16. Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses.
Hendrix N; Kim DD; Patel KS; Devine B
Med Decis Making; 2021 Apr; 41(3):366-372. PubMed ID: 33451278
[TBL] [Abstract][Full Text] [Related]
17. Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review.
Avanceña ALV; Prosser LA
Value Health; 2021 Jan; 24(1):136-143. PubMed ID: 33431148
[TBL] [Abstract][Full Text] [Related]
18. Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses.
Kwok MQT; Kareem MA; Cash MJ; Lafferty F; Tobin K; O'Mahony JF
Pharmacoeconomics; 2020 Aug; 38(8):809-818. PubMed ID: 32342439
[TBL] [Abstract][Full Text] [Related]
19. A review of cost-effectiveness analyses in rheumatology and related disciplines.
Maetzel A; Ferraz MB; Bombardier C
Curr Opin Rheumatol; 1998 Mar; 10(2):136-40. PubMed ID: 9567209
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.
Siegel JE; Weinstein MC; Russell LB; Gold MR
JAMA; 1996 Oct 23-30; 276(16):1339-41. PubMed ID: 8861994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
